Abstract
Personalized Oncology has advanced through genomic & proteomic platforms. BCR-abl; EGFr & ALK have provided drug-able targets & companion diagnostics in several diseases, yet many transforming events in humans are polygenic, complex & incompletely understood at a genomic level. Recognition that oncogenesis reflects changes in the cell and its environment has renewed interest in whole cell…